Sirolimus safety with routine vaccines for a rare blood vessel tumor
Part of Cancer clinical trials.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child with kaposiform hemangioendothelioma (KHE) and will be treated with sirolimus, or you are a healthy child for the comparison group
- You will receive vaccines in the planned schedule, based on lab check results and a doctor’s advice
- Vaccines may include either live vaccines or inactivated (killed) vaccines, given at the right times
- No current serious infection at the time of blood testing (and not hepatitis B markers like HBsAg/HBeAg positive)
- You do not have a history of immune problems or low immunoglobulin (immune protein) levels
- You can and will agree to take part (informed consent not withdrawn)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to stop taking sirolimus for children with KHE, a rare blood vessel tumor. It helps find the best plan to prevent the tumor from coming back after treatment.
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
This study tests sirolimus for people with a rare blood-vessel cancer called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can control the disease and improve symptoms. It's for people who can't have surgery to remove the cancer and need systemic treatment.
This trial tests whether the drug sirolimus (rapamycin) can help people with dilated cardiomyopathy who also have a specific virus (KSHV) in their blood. It aims to see if sirolimus can improve heart function.
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Hear when a new Kaposiform Hemangioendothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.